Therapeutic potential of octreotide in the treatment of liver metastases

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 1, 1996, Pages 23-31

  Davies, Nick ^a   Cooke, Timothy G ^b   Jenkins, Spencer A ^c  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Colorectal cancer; Liver metastases; Octreotide; Surgery

Indexed keywords

CYTOTOXIC AGENT; FLUOROURACIL; LEVAMISOLE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GRAFT; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; LIVER METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; STEATORRHEA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; CLINICAL TRIALS; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM STAGING; OCTREOTIDE; RATS;

EID: 0030020923     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199601001-00005     Document Type: Review

References (41)

1. Steele G. Adjuvant therapy for patients with colon and rectal cancer: clinical indications for multimodality therapy in high-risk groups and specific surgical questions for future multimodality trials. Surgery 1992; 112: 847-849.
2. Townsend CM, Singh P, Thompson JC. Gastrointestinal hormones and gastrointestinal and pancreatic cancer. Gastroenterology 1986; 91: 1002-1006.
3. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977-6985.
4. Parmar H, Bogden A, Mollard M, et al. Somatostatin and somatostin analogues in oncology. Cancer Treatment Rev 1989; 16: 95-115.
5. Weckbecker G, Raulf F, Stolz B, et al. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993; 60: 245-264.
6. Marbach P, Brinner U, Lemarie M, et al. From somatostatin to Sandostatin: pharmacodynamics and pharmacokinetics. Metabolism 1992; 41: 7-10.
7. Nott DM, Baxter JN, Grimes JS, et al. Effects of a somatostatin analogue (SMS 201-995) on the growth and development of hepatic tumour derived by intraportal injection of Walker cells in rats. Br J Surg 1989; 76: 1149-1151.
8. Davies N, Kynaston H, Yates J, et al. Octreotide inhibits the growth and development of three types of experimental liver metastases. Br J Surg 1995; 82: 840-843.
9. Van Eijck CHJ, Slooter GD, Hofland LJ, et al. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Br J Surg 1994; 81: 1333-1337.
10. Qin Y, Schally AV, Willems G. Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int J Cancer 1992; 52: 791-796.
11. Stewart GJ, Lawson JA, Morris DL. Octreoptide inhibits development of hepatic metastases from a human colonic cancer cell line. Br J Surg 1994; 81: 1332.
12. Davies N. Octreotide and Experimental Liver Tumour. MD thesis, Birmingham University, 1994.
13. Yamada Y, Reissine T, Law SF, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenyl cyclase. Mol Endocrinol 1992; 6: 2136-2142.
14. Bruno JF, Xu Y, Song J, et al. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 1992; 89: 11151-11155.
15. Roher L, Raulfe F, Bruns C, et al. Cloning and characterisation of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993; 90: 4196-4200.
16. Miller GV, Farmey SM, Woodhouse LF, et al. Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br J Cancer 1992; 66: 391-395.
17. Miller GV, Preston SR, Woodhouse LF, et al. Somatostatin binding in human gastrointestinal tissues: effects of cations and somatostin analogues. Gut 1993; 34: 1351-1356.
18. Baxter JN, Jenkins SA, Day DW, et al. Effects of somatostatin analogue (SMS201-995) on hepatic and splenic reticuloendothelial function in the rat. Br J Surg 1985; 72: 1005-1008.
19. Jenkins SA, Ellenbogen S, Baxter J, et al. Sandostatin (SMS) in the long term management of portal hypertension: a prelimimary prospective randomised controlled clinical trial. HPB Surg 1992; 5 (suppl): 29.
20. Davies N, Kynaston H, Yates J, et al. Octreotide, the hepatic reticuloendothelial system and liver metastases. Gut 1995; 36: 610-614.
21. Davies N, Kynaston H, Yates J, et al. Reticuloendothelial stimulation: levamisole compared. Dis Colon Rect 1993; 36: 1054-1058.
22. Bouwens L, Wisse E. Immuno-electron microscopic characterization of large granular lymphocytes (natural killer cells) from rat liver. Eur J Immunol 1987; 17: 1423-1428.
23. Archer SG, Gray BN. Vascularization of small liver metastases. Br J Surg 1989; 76: 545-548.
24. Bengmark S. Palliative treatment of hepatic tumours. Br J Surg 1989; 76: 771-773.
25. Jenkins SA, Baxter JN, Corbett WA, et al. Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985; 72: 1009-1012.
26. Hemmingway DM, Jenkins SA, Cooke TG. The effects of Sandostatin (octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases. Br J Cancer 1992; 65: 396-398.
27. Davies N, Kynaston H, Yates J, et al. Reduction of liver tumour growth and blood flow by octreotide [abstract]. Br J Surg 1993; 80: 651.
28. Weber C, Merriam L, Koschitzky T, et al. Inhibition of the growth of human breast carcinomas in vivo by somatostatin analogue SMS 201-995: treatment of nude mouse xenografts. Surgery 1989; 106: 416-419.
29. Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991; 50: 245-251.
30. Fassler JE, Hughes JH, Cataland S, et al. Somatostatin analogue: an inhibitor of angiogenesis? Biomed Res 1988; (suppl): 181-185.
31. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumour-host interaction? Int J Cancer 1994; 56: 681-688.
32. Ichihashi H, Mabuchi H, Suenaga M, et al. Liver regeneration and tumour growth in rats after partial hepatectomy. Jpn J Surg 1984; 14: 510-514.
33. Davies N, Kynaston H, Yates J, et al. A somatostatin analogue inhibits tumour growth in regenerating liver [abstract]. Br J Surg 1993; 80: 1482.
34. Davies N, Kynaston H, Yates J, et al. Octreotide inhibits liver regeneration in the rat [abstract]. Hepatology 1992; 16: 527.
35. Palmer Smith J, Doll D, Croitoru R, et al. Octreotide has no effect on advanced colon cancer. J Clin Gastroenterol 1994; 18: 245-247.
36. Klijn JGM, Hoff AM, Planting AST, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990; 62: 627-630.
37. Friess H, Buchler M, Beglinger C, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8: 540-545.
38. Ebert M, Friess H, Beger HG, et al. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994; 55 (suppl 1): 48-51.
39. Khoo D, Hall E, Motson R, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30A: 28-30.
40. Szabo S, Usadel KH. Cytoprotection-organoprotection by somatostatin: gastric and hepatic lesions. Experientia 1982; 38: 254-256.
41. Usadel KH, Kessler H, Rohr G, et al. Cytoprotective peptides of somatostatin. Klin Wochenschr 1986; 64 (suppl 7): 59-63.